Skip to content
Peptide.Guide
PreclinicalMuscleSubQDailyUncontrolled myostatin inhibition may have cardiac and tendon risksPartial data

Follistatin-344

Myostatin inhibitor investigated for muscle hypertrophy, muscular dystrophy, and body composition.

Read dosing protocol

§ 01   Overview

Overview

Myostatin inhibitor investigated for muscle hypertrophy, muscular dystrophy, and body composition.

Gene therapy and peptide forms studied in dystrophy trials. Research chemical status for peptide form.

§ 02   Mechanism

Mechanism of action

Follistatin-344 binds and neutralizes myostatin and activins, releasing the brake on muscle growth. It also has effects on inhibin signaling.

  • 01Muscle hypertrophy in preclinical models
  • 02Investigated for muscular dystrophy

§ 03   Dosing

Dosing protocol

Standard Protocol

Dose Range
100 – 300 mcg (research)
Route
SubQ
Frequency
Daily
Cycle
Short cycles (2–4 weeks)

§ 04   Evidence

Evidence & research

Preclinical

Gene therapy and peptide forms studied in dystrophy trials. Research chemical status for peptide form.

FDA Status

Not FDA-approved. WADA prohibited.

§ 06   News

In the news

8 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Research-only, no commercial channel

No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09   Safety

Safety & side effects

Side effects

  • 01Tendon strain with rapid hypertrophy
  • 02Cardiac risk theoretical (cardiac myostatin signaling)

Contraindications

None specified.

§ 10   Questions

Follistatin-344 FAQ

What is Follistatin-344?
Myostatin inhibitor investigated for muscle hypertrophy, muscular dystrophy, and body composition. Follistatin-344 binds and neutralizes myostatin and activins, releasing the brake on muscle growth. It also has effects on inhibin signaling.
What is Follistatin-344 used for?
Reported uses include muscle hypertrophy in preclinical models and investigated for muscular dystrophy. Evidence strength is rated Preclinical — see the evidence section for detail.
How is Follistatin-344 dosed?
Commonly referenced dosing is 100 – 300 mcg (research), typically daily, administered SubQ. This is educational reference only; consult a licensed clinician before use.
What are the side effects of Follistatin-344?
Commonly reported side effects include tendon strain with rapid hypertrophy and cardiac risk theoretical (cardiac myostatin signaling). This list is not exhaustive.
Is Follistatin-344 legal?
No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established. FDA status: Not FDA-approved. WADA prohibited..
◆   In this categoryMore from Muscle
01

Follistatin-315

Circulating follistatin isoform (315 aa). Same myostatin/activin neutralization as FS-344 but shorter half-life due to loss of heparin-binding C-terminus.

Preclinical
02

Bimagrumab

Fully human mAb against activin type-II receptors. Failed sarcopenia and sIBM endpoints; now developed by Lilly for obesity in combination with tirzepatide (BELIEVE trial).

Clinical
03

ACE-031 (Ramatercept)

Soluble ActRIIB-Fc fusion decoy receptor. DMD Phase 2 halted in 2013 due to epistaxis and telangiectasia from vascular off-target effects.

Clinical
04

ACE-083

Locally acting follistatin-Fc fusion for intramuscular hypertrophy. FSHD and CMT Phase 2 trials failed functional endpoints; discontinued.

Clinical
05

PEG-MGF

PEGylated 24-aa IGF-1Ec E-peptide that activates muscle satellite cells via a non-IGF-1R pathway. Grey-market use with no registered trials.

Preclinical

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.